| Symbiose 2.0 (transkript 8-9, p.11, 2010) |
| Der
Lohn des Risikos (transkript 6, p. 11, 2009) |
| Pharmazeutische
R&D-Pipeline (GoingPublic 5, pp. 52-53, 2005) |
| GPC
Biotech und Agennix fusionieren (Biospektrum 15, p. 329, 2009) |
| Gastanalyse:
biolitec AG (Smart Investor 8, pp. 60-61, 2007) |
| Große Spannbreite (transkript 9, p. 11, 2011 |
| Gastanalyse Eckert & Zigler AG (Smart Investor 9, pp. 62-63, 2011) |
| Medizintechnik (GoingPublic, Sonderbeilage Medzintechnik 2011, pp. 24-27, 2011) |
| Original
and White Label Research (Selected Samples) |
Compendium
of the Life Science Industry |
| Challenges
and Obstacles of Biotechnology in Germany (in preparation, due Ocober 2012) |
| Evolution
of Business Models in Biotechnology (in preparation, due October 2012) |
|
